Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype, ...
The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results